BioMedNewsBreaks

FridayJul 02, 2021 10:38 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth…

Continue Reading

FridayJul 02, 2021 10:23 am

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Pediatric NeuroCap Is First-of-its-Kind for Pediatric Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is bringing to market new technology that allows EEG testing to be deployed rapidly and accurately in children and adolescents. The Pediatric NeuroCap is intended to solve significant barriers limiting EEG monitoring in pediatric care. “Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific fully adapted its revolutionary NeuroCap to be used in children,” reads a recent article. “The Pediatric NeuroCap comes in two sizes and includes 22 integrated, pre-gelled electrodes compliant with the 10-20 international system. With the…

Continue Reading

ThursdayJul 01, 2021 2:53 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth between images and rely on memory to resect. “The company’s advanced technology will show both images simultaneously side-by-side on one screen, providing surgeons with better visualization to remove the cancer and making procedures more efficient,”…

Continue Reading

ThursdayJul 01, 2021 12:53 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the last 60 days alone, we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS’ operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a…

Continue Reading

ThursdayJul 01, 2021 12:36 pm

BioMedNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s founder and Chief Medical Officer Dr. G. Dave Singh shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product. “Dr. Singh’s primary goal with this book is to spread…

Continue Reading

ThursdayJul 01, 2021 12:20 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. Fluence, a psychedelic therapy educational platform, will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials, while Clinlogix, a global novel pharmaceutical product contract research organization, will provide support services. “Tryp announced on May 25 that global pharmaceutical contract development and…

Continue Reading

WednesdayJun 30, 2021 2:54 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Enters Strategic Partnerships to Amplify Message Through Global Expansion

RYAH Group (CSE: RYAH) today announced that it has entered into two public relations, investor relations and/or marketing arrangements. These include a service agreement with KCSA Strategic Communications, through RYAH Medtech Inc., under which KCSA will provide certain public relations and corporate communications services, as well as a service agreement with EastWest Asset Management LLC, an affiliate of CFN Media Group, through RYAH Medtech, under which EastWest will provide certain investor relations, marketing and corporate communication services to the company. “We continue to remain focused and disciplined in ensuring our clients, investors and our partners remain informed of our vision,…

Continue Reading

WednesdayJun 30, 2021 11:11 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines the delivery of approximately 1,000 of XPhyto’s proprietary Covid-ID Lab tests to test centers in Berlin. Delivery is scheduled to begin this week, followed by a brief trial period to integrate and evaluate XPhyto’s new PCR test system with commercial operations expected to commence upon delivery…

Continue Reading

WednesdayJun 30, 2021 10:12 am

BioMedNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2021 Financial Results, Corporate Highlights

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial results for fiscal year ended March 31, 2021; the company also provided a corporate update, noting that its PALISADE-1 phase 3 trial designed to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (“SAD”) is under way. The announcement also noted that the company is preparing to initiate several exploratory phase 2A clinical trials of…

Continue Reading

TuesdayJun 29, 2021 11:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). An anthracycline, Berubicin falls in a class of anticancer agents that are among the most powerful chemotherapy drugs, proven to be effective against more types of cancer than any other category of chemotherapeutic agents. Fast…

Continue Reading